The phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance) and fulvestrant (Faslodex) as a first-line treatment for people with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer showed positive results.
Vanderbilt researchers led a clinical trial combining atezolizumab (Tecentriq), an immunotherapy, in combination with chemotherapy in patients with metastatic triple-negative breast cancer to both evaluate the efficacy of the treatment combination and to understand biomarkers of response to immunotherapy.
A decision-making aid to help women at high risk of breast cancer decide whether to add MRIs to their screening regimen has proved popular with both patients and doctors alike in early testing.
For many individuals living in the rural 23-county area of North Central Florida served by the UF Health Cancer Center, access to mammography services for breast cancer screening is limited.
The FY24 Defense Appropriations Act is anticipated to provide funding for the BCRP to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for Service Members and their Families, Veterans, and the general public.
FDA approved Truqap (capivasertib) with fulvestrant for adult patients with hormone receptor-positive, human epidermal growth factor receptor-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.
Three patients in Mozambique have started treatment for HER2- HR+ advanced breast cancer, including CDK4/6 inhibitor therapy through The Max Foundation’s Max Access Solutions program.
A retrospective study led by University of Cincinnati Cancer Center researchers showed that a device that acts as a GPS for surgeons to locate and remove breast and lymph node tumors was safe and effective.
After 27.7 months of follow-up in the phase III NATALEE trial, the invasive disease-free survival benefit with Kisqali (ribociclib) plus endocrine therapy was consistent across key prespecified subgroups, compared to ET alone, in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC).
The phase III monarchE study evaluating two years of adjuvant Verzenio (abemaciclib) in combination with endocrine therapy compared with ET alone in patients with HR+, HER2-, node-positive early breast cancer at a high risk of recurrence demonstrated long-term impact.
